Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Raymond James Downgrades Bristol-Myers Squibb to Market Perform

Raymond James analyst Dane Leone downgrades Bristol-Myers Squibb (NYSE:BMY) from Outperform to Market Perform.

byBenzinga Newsdesk

June 6, 2022

1 minute read

Raymond James analyst Dane Leone downgrades Bristol-Myers Squibb (NYSE:BMY) from Outperform to Market Perform.

Essent: Q2 Earnings Insights

By Benzinga Insights

Today, 6:59 AM

Essent Gr (NYSE:ESNT) reported its Q2 earnings results on Friday, August 5, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

ESNT

J.Jill’s Debt Overview

By Benzinga Insights

Today, 6:59 AM

Shares of J.Jill (NYSE:JILL) moved lower by 5.38% in the past three months. Before having a look at the importance of debt, let us look at how much debt J.Jill has.

JILL

Morgan Stanley Initiates Coverage On FIGS with Equal-Weight Rating, Announces Price Target of $34

By Benzinga Newsdesk

Today, 6:59 AM

Morgan Stanley analyst Lauren Schenk initiates coverage on FIGS (NYSE:FIGS) with a Equal-Weight rating and announces Price Target of $34.

FIGS

Core & Main Q3 EPS $0.39 Beats $0.30 Estimate, Sales $1.40B Beat $1.29B Estimate

By Bill Haddad

Today, 6:59 AM

Core & Main (NYSE:CNM) reported quarterly earnings of $0.39 per share which beat the analyst consensus estimate of $0.30 by 30 percent. The company reported quarterly sales of $1.40 billion which beat the analyst

CNM

Raymond James Downgrades Bristol-Myers Squibb to Market Perform

Related Posts

Essent: Q2 Earnings Insights

J.Jill’s Debt Overview

Morgan Stanley Initiates Coverage On FIGS with Equal-Weight Rating, Announces Price Target of $34

Core & Main Q3 EPS $0.39 Beats $0.30 Estimate, Sales $1.40B Beat $1.29B Estimate